Abbott Laboratories' (ABT) fourth-quarter results were weighed down by weakness in its Nutrition business, but the stock's pullback presents an opportunity, supported by resilient earnings and strong MedTech growth, UBS Securities said in a Thursday note.

UBS noted that despite Abbott's organic sales growth, excluding COVID, slowing to 3.8% in the fourth quarter, it remains confident in management's 2026 organic growth guidance of 6.5% to 7.5%, citing underappreciated MedTech tailwinds.

The brokerage highlighted a rebound in electrophysiology following the US Volt launch, potential upside from an upcoming large left atrial appendage closure trial, and strong demand for Libre continuous glucose monitoring products.

While uncertainty remains in Nutrition, which accounts for about 20% of sales, UBS said MedTech strength and accelerating growth into 2026 support a more positive view on the stock.

UBS maintained its buy rating with a price target of $158.

Shares of Abbott Laboratories were down 1.3% in recent Friday trading.

Price: 107.04, Change: -1.57, Percent Change: -1.45